Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q5DRB9

Entry ID Method Resolution Chain Position Source
AF-Q5DRB9-F1 Predicted AlphaFoldDB

No variants for Q5DRB9

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for Q5DRB9

No associated diseases with Q5DRB9

2 regional properties for Q5DRB9

Type Name Position InterPro Accession
domain Glycoside hydrolase family 18, catalytic domain 79 - 393 IPR001223
domain Chitinase II 79 - 385 IPR011583

Functions

Description
EC Number
Subcellular Localization
  • Cell membrane ; Single-pass type I membrane protein
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

1 GO annotations of cellular component

Name Definition
integral component of plasma membrane The component of the plasma membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.

1 GO annotations of molecular function

Name Definition
calcium ion binding Binding to a calcium ion (Ca2+).

3 GO annotations of biological process

Name Definition
cell adhesion The attachment of a cell, either to another cell or to an underlying substrate such as the extracellular matrix, via cell adhesion molecules.
homophilic cell adhesion via plasma membrane adhesion molecules The attachment of a plasma membrane adhesion molecule in one cell to an identical molecule in an adjacent cell.
nervous system development The process whose specific outcome is the progression of nervous tissue over time, from its formation to its mature state.

1 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
O60330 PCDHGA12 Protocadherin gamma-A12 Homo sapiens (Human) PR
10 20 30 40 50 60
MIPARLHRDY KGLVLLGILL GTLWETGCTQ IRYSVPEELE KGSRVGDISR DLGLEPRELA
70 80 90 100 110 120
ERGVRIIPRG RTQLFALNPR SGSLVTAGRI DREELCMGAI KCQLNLDILM EDKVKIYGVE
130 140 150 160 170 180
VEVRDINDNA PYFRESELEI KISENAATEM RFPLPHAWDP DIGKNSLQSY ELSPNTHFSL
190 200 210 220 230 240
IVQNGADGSK YPELVLKRAL DREEKAAHHL VLTASDGGDP VRTGTARIRV MVLDANDNAP
250 260 270 280 290 300
AFAQPEYRAS VPENLALGTQ LLVVNATDPD EGVNAEVRYS FRSVDDKAAQ VFKLDCNSGT
310 320 330 340 350 360
ISTIGELDHE ESGFYQMEVQ AMDNAGYSAR AKVLITVLDV NDNAPEVVLT SLASSVPENS
370 380 390 400 410 420
PRGTLIALLN VNDQDSEENG QVICFIQGNL PFKLEKSYGN YYSLVTDIVL DREQVPSYNI
430 440 450 460 470 480
TVTATDRGTP PLSTETHISL NVADTNDNPP VFPQASYSAY IPENNPRGVS LVSVTAHDPD
490 500 510 520 530 540
CEENAQITYS LAENTIQGAS LSSYVSINSD TGVLYALSSF DYEQFRDLQV KVMARDNGHP
550 560 570 580 590 600
PLSSNVSLSL FVLDQNDNAP EILYPALPTD GSTSVELAPR SAEPGYLVTK VVAVDRDSGQ
610 620 630 640 650 660
NAWLSYRLLK ASEPGLFSVG LHTGEVRTAR ALLDRDALKQ SLVVAVQDHG QPPLSATVTL
670 680 690 700 710 720
TVAVANSIPQ VLADLGSLES PANSETSDLT LYLVVAVAAV SCVFLAFVIL LLALRLRRWH
730 740 750 760 770 780
KSRLLQASGG GLTGAPASHF VGVDGVQAFL QTYSHEVSLT TDSRRSHLIF PQPNYADMLV
790 800 810 820 830 840
SQESFEKSEP LLLSGDSVFS KDGHGLIEQA PPNTDWRFSQ AQRPGTSGSQ NGDDTGTWPN
850 860 870 880 890 900
NQFDTEMLQA MILASASEAA DGSSTLGGGA GTMGLSARYG PQFTLQHVPD YRQNVYIPGS
910 920 930
NATLTNAAGK RDGKAPAGGN GNKKKSGKKE KK